Validation of the Graded Prognostic Assessment for Patients with Lung Cancer and Brain Metastases
Soon Woo Hong,
Korea Republic of
PD-0967
Abstract
Validation of the Graded Prognostic Assessment for Patients with Lung Cancer and Brain Metastases
Authors: Soon Woo Hong1, Changhoon Song2, Wan Jeon3, Jae-Sung Kim4
1Seoul National University Hospital, Department of Radiation Oncology, Seoul, Korea Republic of; 2Seoul National University Bundang Hospital, Department of Radiation Oncology , Seongnam, Korea Republic of; 3Dongnam Institute of Radiological and Medical Science, Department of Radiation Oncology, Busan, Korea Republic of; 4Seoul National University Bundang Hospital, Department of Radiation Oncology, Seongnam, Korea Republic of
Show Affiliations
Hide Affiliations
Purpose or Objective
Patients with non-small cell lung cancer (NSCLC) and brain metastases represent a markedly heterogeneous population. The original diagnosis-specific graded prognostic assessment is a prognostic index based on data from patients diagnosed between 1985 and 2005 and includes patients age, performance status, extracranial disease, and number of brain metastases. An updated prognostic index (Lung-molGPA) that incorporates molecular features (EGFR and ALK alterations) was created in 2016 based on the North American retrospective database analysis of 2186 patients with NSCLC and newly diagnosed brain metastases between 2006 and 2014. The aim of this study is to validate the Lung-molGPA model in an independent Asian patient population
Material and Methods
Four hundred thirty-three patients (368 adenocarcinoma and 65 nonadenocarcinoma) with NSCLC with newly diagnosed brain metastasis between 2005 and 2017 were reviewed retrospectively and scored using the Lung-molGPA model.
Results
The overall median survival for the cohort in the present study was 14 months (16.5 months in the adenocarcinoma and 8.0 months in the nonadenocarcinoma, respectively; p = 0.003). For patients with adenocarcinoma, the median survival for patients with a Lung-molGPA score of 3.5 to 4.0 was 44.7 months, while the median survival was only 8.9 months in patients scoring 0–1.0, 17.0 months in patients scoring 1.5–2.0, and 30.2 months for scores of 2.5–3.0 (p <0.0001). For patients with nonadenocarcinoma, the median survival for scores 0–1.0, 1.5–2.0, and 2.5–3.0 were 6.7, 10.3, and 13.2 months, respectively (p = 0.038).
Conclusion
Survival for patients with NSCLC and brain metastases varies widely. This study provides an independent validation of the 2016 Lung-molGPA in Asian patients.